02:10 PM EST, 03/07/2024 (MT Newswires) -- Werewolf Therapeutics ( HOWL ) reported a Q4 net loss Thursday of $0.33 per diluted share, narrowing from a loss of $0.39 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.43.

Collaboration revenue for the quarter ended Dec. 31 was $1.5 million, down from $7.3 million a year ago. Analysts surveyed by Capital IQ expected $1.9 million.

As of Dec. 31, the company said it had $134.3 million in cash and cash equivalents, and expected it could finance operations through at least Q2 2025.

Price: 6.96, Change: -0.08, Percent Change: -1.07